Refractory autoimmune thrombocytopenic purpura treatment with Rituximab

被引：29

作者：

Patel, K ^{[1
]}

Berman, J ^{[1
]}

Ferber, A ^{[1
]}

Caro, J ^{[1
]}

机构：

[1] Thomas Jefferson Univ Hosp, Dept Med Hematol Oncol, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2001年 / 67卷 / 01期

关键词：

D O I：

10.1002/ajh.1081

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：59 / 60

页数：2

共 5 条

[1] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[2]

Mow BM, 1999, BLOOD, V94, p82B

[3]

PERROTA A, 1999, BLOOD S1, V94, P14

[4] Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease [J].

Ratanatharathorn, V ;

Carson, E ;

Reynolds, C ;

Ayash, LJ ;

Levine, J ;

Yanik, G ;

Silver, SM ;

Ferrara, JLM ;

Uberti, JP .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :275-279

[5]

REFF ME, 1994, BLOOD, V83, P435

← 1 →